Please provide your email address to receive an email when new articles are posted on . An association was found between uremic pruritis and adverse long-term outcomes for patients on dialysis, ...

WASHINGTON, DC — The intensity of itch experienced by patients on hemodialysis with uremic pruritus can be eased with 12 weeks of treatment with difelikefalin (Korsuva, Cara Therapeutics), results ...

Uremic pruritus is a debilitating symptom frequently encountered in individuals with chronic kidney disease (CKD), particularly those receiving haemodialysis. This condition, characterised by ...

Trevi Therapeutics announced statistically significant results from its Phase 2/3 trial of Nalbuphine ER for the treatment of moderate to severe uremic pruritus. Uremic pruritus is a persistent and ...

Please provide your email address to receive an email when new articles are posted on . The National Kidney Foundation recently hosted a live event, as a part of its NKF Live series, to discuss uremic ...

In a phase 3 trial, difelikefalin, a kappa opioid receptor agonist, significant decreased itching and improved itching-related quality of life among dialysis patients suffering from pruritus.

NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc. (“Trevi” or the “Company”), a late-stage clinical development company developing oral Nalbuphine ER for chronic pruritus conditions, today ...

Insulin Dose Not Linked to Greater Mortality, ACCORD Trial Reveals In an 8-week randomized trial, extended-release nalbuphine 120 mg BID significantly reduced itch severity compared with placebo. SAN ...

(RTTNews) - Cara Therapeutics Inc. (CARA), an early commercial-stage biopharmaceutical company, announced Wednesday that its licensing partner Maruishi Pharmaceutical Co., Ltd. submitted a New Drug ...

Cara Therapeutics is developing an oral formulation for pruritus associated with various conditions after FDA-approved intravenous difelikefalin for ESRD patients. Although the primary endpoint was ...